Primary Site >> Colorectal Cancer

Gene >> FCGR2A

Journal: Cancer Immunol Immunother. 1992;35(3):158-64.
Title: Cytotoxic functions of blood mononuclear cells in patients with colorectal carcinoma treated with mAb 17-1A and granulocyte/macrophage-colony-stimulating factor.
Author: Ragnhammar, P|Masucci, G|Frodin, J E|Hjelm, A L|Mellstedt, H
PMID: 1638551
Journal: Int J Immunopharmacol. 1997 Aug;19(8):413-20.
Title: Prothymosin alpha 1 effects in vitro on chemotaxis, cytotoxicity and oxidative response of neutrophils from melanoma, colorectal and breast tumor patients.
Author: Heidecke, H|Eckert, K|Schulze-Forster, K|Maurer, H R
PMID: 9568546
Journal: Ann Oncol. 1998 Apr;9(4):453-5.
Title: Irinotecan-induced immune thrombocytopenia.
Author: Bozec, L|Bierling, P|Fromont, P|Levi, F|Debat, P|Cvitkovic, E|Misset, J L
PMID: 9636839
Journal: J Thromb Haemost. 2009 Jan;7(1):171-81.
Title: Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice.
Author: Meyer, T|Robles-Carrillo, L|Robson, T|Langer, F|Desai, H|Davila, M|Amaya, M|Francis, J L|Amirkhosravi, A
PMID: 18983497
Journal: BMC Cancer. 2011 Nov 25;11:496.
Title: Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer.
Author: Dahan, Laetitia|Norguet, Emmanuelle|Etienne-Grimaldi, Marie-Christine|Formento, Jean-Louis|Gasmi, Mohamed|Nanni, Isabelle|Gaudart, Jean|Garcia, Stephane|Ouafik, L'Houcine|Seitz, Jean-Francois|Milano, Gerard
PMID: 22117530
Journal: Br J Clin Pharmacol. 2012 May;73(5):776-85.
Title: Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan.
Author: Etienne-Grimaldi, Marie-Christine|Bennouna, Jaafar|Formento, Jean-Louis|Douillard, Jean-Yves|Francoual, Mireille|Hennebelle, Isabelle|Chatelut, Etienne|Francois, Eric|Faroux, Roger|El Hannani, Chaza|Jacob, Jacques-Henri|Milano, Gerard
PMID: 22486600
Journal: Anticancer Res. 2013 Nov;33(11):4995-8.
Title: Predicting skin toxicity according to EGFR polymorphisms in patients with colorectal cancer receiving antibody against EGFR.
Author: Saito, Rie|Suzuki, Hideo|Yamada, Takeshi|Endo, Shinji|Moriwaki, Toshikazu|Ueno, Takunori|Hirose, Mitsuaki|Hirai, Sachiko|Yamato, Kenji|Mizokami, Yuji|Hyodo, Ichinosuke
PMID: 24222141
Journal: Clin Cancer Res. 2016 May 15;22(10):2435-44.
Title: Fc-gamma Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer.
Author: Liu, Geoffrey|Tu, Dongsheng|Lewis, Marcia|Cheng, Dangxiao|Sullivan, Leslie A|Chen, Zhuo|Morgen, Eric|Simes, John|Price, Timothy J|Tebbutt, Niall C|Shapiro, Jeremy D|Jeffery, G Mark|Mellor, J Daniel|Mikeska, Thomas|Virk, Shakeel|Shepherd, Lois E|Jonker, De
PMID: 27179112
Journal: Clin Cancer Res. 2016 Oct 1;22(19):4958.
Title: FCGR, Cetuximab, and Colorectal Cancer Survival-Letter.
Author: Negri, Francesca V|Boggiani, Daniela|Rimanti, Anita|Musolino, Antonino
PMID: 27697992
Journal: Pharmacogenomics J. 2017 Dec;17(6):535-542.
Title: Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis.
Author: Morgen, E K|Lenz, H-J|Jonker, D J|Tu, D|Milano, G|Graziano, F|Zalcberg, J|Karapetis, C S|Dobrovic, A|O'Callaghan, C J|Liu, G
PMID: 27897268
Journal: Clin Transl Oncol. 2017 Aug;19(8):1018-1027.
Title: Associations between single-nucleotide polymorphisms and inflammatory bowel disease-associated colorectal cancers in inflammatory bowel disease patients: a meta-analysis.
Author: Li, H|Jin, Z|Li, X|Wu, L|Jin, J
PMID: 28243990
Journal: Pharmacogenomics J. 2018 May 22;18(3):474-479.
Title: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab.
Author: Magnes, T|Melchardt, T|Hufnagl, C|Weiss, L|Mittermair, C|Neureiter, D|Klieser, E|Rinnerthaler, G|Roesch, S|Gaggl, A|Greil, R|Egle, A
PMID: 28719596
Journal: Cancer Med. 2018 Oct 14.
Title: Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer.
Author: Shepshelovich, Daniel|Townsend, Amanda R|Espin-Garcia, Osvaldo|Latifovic, Lidija|O'Callaghan, Chris J|Jonker, Derek J|Tu, Dongsheng|Chen, Eric|Morgen, Eric|Price, Timothy J|Shapiro, Jeremy|Siu, Lillian L|Kubo, Michiaki|Dobrovic, Alexander|Ratain, Mark J|X
PMID: 30318772